AlloVir, Inc.

NasdaqCM:ALVR Stock Report

Market Cap: US$48.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AlloVir Management

Management criteria checks 4/4

AlloVir's CEO is Vikas Sinha, appointed in Jan 2019, has a tenure of 6.17 years. total yearly compensation is $544.40K, comprised of 69% salary and 31% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth $416.19K. The average tenure of the management team and the board of directors is 6.2 years and 3.8 years respectively.

Key information

Vikas Sinha

Chief executive officer

US$544.4k

Total compensation

CEO salary percentage68.97%
CEO tenure6.2yrs
CEO ownership0.9%
Management average tenure6.2yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Analysis Article • Oct 29

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 13

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 09

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 03

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 23

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Mar 02

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 11

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 04

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir press release (NASDAQ:ALVR): Q2 GAAP EPS of $0.69 beats by $1.42. For the quarter ended June 30, 2022, net loss was $44.6 million or $0.69 per share, compared with a net loss of $37.6 million or $0.60 per share for the quarter ended June 30, 2021.
Seeking Alpha • Jul 27

AlloVir stock surges on $126.6M securities offering

AlloVir (NASDAQ:ALVR) shares gained over 8% pre-market on Wednesday after the immunotherapy company announced a $126.6M securities offering. The firm entered into a securities purchase agreement with a group of institutional and strategic investors to sell ~25.46M shares of common stock at a purchase price of $4.61/share. Gross proceeds will be ~$126.6M, with the offering expected to close on or about July 28, 2022. Net proceeds, together with existing cash, cash equivalents and investments, will be used to complete enrollment and achieve data readouts in all three of the company’s ongoing Phase 3 trials of its lead multi-virus specific T-cell therapy candidate, posoleucel, for the continued advancement of manufacturing processes to support regulatory submissions, for other research and development activities for its product candidates, and for general corporate purposes. As of June 30, 2022, AlloVir's (ALVR) cash, cash equivalents and short-term investments stood at $172.7M.
Analysis Article • Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 21

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 07

AlloVir: A Comparative Study Of Its Manufacturing Process

AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Its technology has similarities and differences with a number of other companies, discussed here. ALVR presents an interesting approach to an unmet medical need.
Analysis Article • Nov 02

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

My readers will get the background on the stem cell transplant issues. I will offer a discussion on the uniqueness that AlloVir offers patients. The outstanding caliber and experience the management team brings to the creation of the company will be shared.
Analysis Article • Aug 06

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of AlloVir, Inc...
Analysis Article • Jul 01

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Apr 01

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Feb 07

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

We wouldn't blame AlloVir, Inc. ( NASDAQ:ALVR ) shareholders if they were a little worried about the fact that Agustin...
Analysis Article • Jan 08

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

A look at the shareholders of AlloVir, Inc. ( NASDAQ:ALVR ) can tell us which group is most powerful. Generally...
Analysis Article • Dec 04

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Vikas Sinha's remuneration changed compared to AlloVir's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$544kUS$375k

-US$59m

Sep 30 2024n/an/a

-US$100m

Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$180m

Dec 31 2023US$3mUS$373k

-US$190m

Sep 30 2023n/an/a

-US$169m

Jun 30 2023n/an/a

-US$167m

Mar 31 2023n/an/a

-US$166m

Dec 31 2022US$3mUS$369k

-US$169m

Sep 30 2022n/an/a

-US$189m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$185m

Dec 31 2021US$7mUS$425k

-US$172m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$117m

Mar 31 2021n/an/a

-US$91m

Dec 31 2020US$6mUS$412k

-US$70m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$2mUS$400k

-US$24m

Compensation vs Market: Vikas's total compensation ($USD544.40K) is about average for companies of similar size in the US market ($USD643.82K).

Compensation vs Earnings: Vikas's compensation has been consistent with company performance over the past year.

CEO

Vikas Sinha (61 yo)

6.2yrs
Tenure
US$544,400
Compensation

Mr. Vikas Sinha, M.B.A., C.A., CPA, is Director of Orna Therapeutics, Inc. from January 2025. Mr. Sinha is CEO of AlloVir, Inc. from December 19, 2024 and has been its Director since January 2019 and serve...

Leadership Team

NamePositionTenureCompensationOwnership
David Hallal
Executive Chairman of the Board6.5yrsUS$227.03k2.45%
$ 1.2m
Vikas Sinha
CEO, President6.2yrsUS$544.40k0.86%
$ 416.2k
Brett Hagen
Chief Accounting Officer6.2yrsUS$796.31k0.016%
$ 8.0k
Edward Miller
General Counsel & Secretary6.2yrsUS$645.69k0.38%
$ 183.2k
Ann Leen
Chief Scientific Officer12.2yrsno datano data
6.2yrs
Average Tenure
58yo
Average Age

Experienced Management: ALVR's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hallal
Executive Chairman of the Board6.5yrsUS$227.03k2.45%
$ 1.2m
Vikas Sinha
CEO, President6.2yrsUS$544.40k0.86%
$ 416.2k
John Mellors
Member of the Scientific Advisory Board2.1yrsno datano data
Malcolm Brenner
Independent Non-Executive Director13.2yrsUS$77.03k0.20%
$ 96.2k
Jeffrey Bornstein
Independent Non-Executive Director4.7yrsUS$94.53k0.065%
$ 31.6k
Michael Boeckh
Member of Scientific Advisory Board2.1yrsno datano data
John DiPersio
Member of Scientific Advisory Board2.1yrsno datano data
Anil Chandraker
Member of Scientific Advisory Board2.1yrsno datano data
Morana Jovan-Embiricos
Independent Non-Executive Director5.8yrsUS$92.03k8.57%
$ 4.2m
Shawn Tomasello
Independent Director3yrsUS$82.03k0.030%
$ 14.7k
Juan Vera
Non-Executive Director11.2yrsUS$67.03k2.06%
$ 997.5k
Gerard Socie
Member of Scientific Advisory Board2.1yrsno datano data
3.8yrs
Average Tenure
59.5yo
Average Age

Experienced Board: ALVR's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 10:06
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AlloVir, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Anupam RamaJ.P. Morgan
Christopher RaymondPiper Sandler Companies